Merck experimental vaccine shows promise in cancer trial: WSJ

(Reuters) – Merck & Co Inc’s experimental cancer vaccine appeared to provide broader protection against a cancer-causing virus than the company’s Gardasil shot did in clinical trials, the Wall Street Journal said on Sunday. Officials at Merck were not immediately available to comment. The article said Merck expects health-care providers to eventually switch to V503 if the product receives marketing approval. Gardasil, launched in 2006, was the first vaccine to protect against human papillomavirus, or HPV, a sexually transmitted virus that can cause cervical cancer in women and other less-common types of cancer in males and females.
Sexual Health News Headlines – Yahoo! News